Hrt Financial LP Fibrogen Inc Transaction History

Hrt Financial LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$0.89 - $2.36 $159,422 - $422,737	179,126 New	179,126 $159,000
Q4 2023 Feb 09, 2024	BUY	$0.38 - $0.91 $104,578 - $250,438	275,207 Added 341.6%	355,770 $315,000
Q3 2023 Nov 13, 2023	BUY	$0.79 - $2.83 $63,644 - $227,993	80,563 New	80,563 $69,000
Q1 2023 May 12, 2023	BUY	$15.95 - $25.18 $3.08 Million - $4.86 Million	193,099 New	193,099 $3.6 Million
Q2 2022 Aug 12, 2022	BUY	$7.94 - $12.96 $128,310 - $209,433	16,160 Added 36.56%	60,356 $637,000
Q1 2022 May 16, 2022	SELL	$12.02 - $16.79 $498,986 - $697,003	-41,513 Reduced 48.43%	44,196 $531,000
Q4 2021 Feb 14, 2022	BUY	$9.93 - $15.39 $851,090 - $1.32 Million	85,709 New	85,709 $1.21 Million
Q4 2019 Feb 14, 2020	SELL	$34.58 - $48.06 $433,460 - $602,432	-12,535 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$36.98 - $48.45 $463,544 - $607,320	12,535 New	12,535 $463,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.